Myosin Therapeutics Revenue and Competitors

Jupiter, FL

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Myosin Therapeutics's estimated annual revenue is currently $930k per year.(i)
  • Myosin Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Myosin Therapeutics has 12 Employees.(i)
  • Myosin Therapeutics grew their employee count by 20% last year.

Myosin Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder and President Board DirectorsReveal Email/Phone
2
Co-Founder and Secretary Board DirectorsReveal Email/Phone
3
Co-Founder and PresidentReveal Email/Phone
4
Investor RelationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.3M995%N/AN/A
#2
$1.1M7-30%N/AN/A
#3
$3.7M244%N/AN/A
#4
$4.3M28-3%N/AN/A
#5
$2.5M16N/AN/AN/A
#6
$0.8M50%N/AN/A
#7
$1.1M70%N/AN/A
#8
$2.5M167%N/AN/A
#9
$1.4M9-25%N/AN/A
#10
$0.6M40%N/AN/A
Add Company

What Is Myosin Therapeutics?

The mission of Myosin Therapeutics, Inc. is to improve health outcomes through the development of novel pharmacotherapies targeting members of the myosin family of molecular motors. Myosin Therapeutics is positioned as the first nanomotor platform company focused on oncology, with a proprietary nMotor system for drug discovery. nMotor is a full screening platform from HTS to validation and target selectivity profiling, enabling Myosin to develop a robust pipeline of oncology therapeutics. Myosin has used nMotor to develop a unique therapeutic to improve outcomes in Glioblastoma (GBM), a critical unmet need with a conservative estimated serviceable market of at least 10,000 cases yearly in the US alone. Additionally, Myosin is developing a unique neurotherapeutic to prevent relapse in METH use disorder, another critical unmet need. METH use disorder is a chronic disorder for which there are currently no FDA-approved medications. More broadly, preclinical studies indicate that first-in-class pharmacotherapeutics targeting NMII have value in many applications, including other substance use disorders, cancer, neural regeneration and infectious diseases. Further, approval of a clinically safe NMII inhibitor will enable scientific advancements into the study of NMII’s contribution to human physiology, such as learning and memory.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$930k

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.3M12N/AN/A
#2
$1.8M12N/AN/A
#3
$1M12-20%N/A
#4
$1.9M129%N/A
#5
$2M14-7%N/A